Loading...
XJPX
4571
Market cap54mUSD
Jul 10, Last price  
106.00JPY
1D
4.95%
1Q
-26.90%
Jan 2017
-88.08%
IPO
-55.52%
Name

NanoCarrier Co Ltd

Chart & Performance

D1W1MN
XJPX:4571 chart
P/E
—
P/S
50.53
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.39%
Rev. gr., 5y
-11.04%
Revenues
174m
+60.80%
103,000,000262,000,000353,000,000117,820,00084,337,000346,344,000373,778,000472,197,000675,801,000243,344,000218,694,000259,096,999496,732,000552,973,000313,264,000264,031,999202,189,000135,508,000108,516,000174,498,000
Net income
-944m
L+12.99%
-729,000,000-494,000,000-524,000,000-494,790,000-555,178,000-398,003,000-484,446,000-1,113,687,000-207,156,000-2,537,148,000-2,676,049,000-5,416,808,000-1,808,510,000-2,009,676,000-2,835,793,000-1,881,678,000-1,310,976,000-780,002,000-835,380,000-943,881,000
CFO
-817m
L+103.35%
-663,000,000-588,172,000-456,620,000-451,999,000-579,114,000-293,705,000-635,329,000-1,086,613,000-1,120,686,000-1,971,089,000-2,525,557,000-4,927,585,000-2,037,259,000-1,138,665,000-1,247,432,000-1,752,992,000-1,087,051,000-585,081,000-401,617,000-816,672,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

NANO MRNA Co., Ltd. specializes in the discovery, advancement, and manufacturing of pharmaceutical products, employing its innovative micellar nanoparticle platform. Its biopharmaceutical pipeline is primarily geared towards addressing oncological conditions and a range of other severe illnesses. The enterprise also undertakes the full spectrum of activities for anti-cancer medications, from initial scientific investigation to market commercialization, all underpinned by its distinctive micellar nanoparticle approach. Established on June 14, 1996, by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi, the firm maintains its principal operations in Tokyo, Japan.
URL
https://www.nanocarrier.co.jp/
IPO date
Mar 05, 2008
Employees
17
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT